Ocular Therapeutix (OCUL) Convertible Debt (2019 - 2023)

Ocular Therapeutix's Convertible Debt history runs 5 years deep, the most recent figure standing at $9.1 million for Q4 2023.

• In Q4 2023, Convertible Debt fell 68.21% year-over-year to $9.1 million; the TTM figure through Dec 2023 stood at $9.1 million (down 68.21% YoY), while the FY2023 annual figure was $9.1 million, down 68.21% from the prior year.
• Convertible Debt was $9.1 million for Q4 2023 at Ocular Therapeutix, up from $8.8 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $30.0 million in Q2 2023 to a low of $8.8 million in Q3 2023.
• Historically, Convertible Debt has averaged $24.3 million across 5 years, with a median of $25.3 million in 2020.
• The sharpest annual moves came in 2020 and 2023: Convertible Debt advanced 10.27% in 2020, then tumbled 68.87% in 2023.
• A 5-year view of Convertible Debt shows it stood at $24.3 million in 2019, then climbed by 0.01% to $24.3 million in 2020, then gained by 8.75% to $26.4 million in 2021, then advanced by 8.75% to $28.7 million in 2022, then plunged by 68.21% to $9.1 million in 2023.
• The last three Convertible Debt figures came in at $9.1 million (Q4 2023), $8.8 million (Q3 2023), and $30.0 million (Q2 2023), per Business Quant data.